Truist Reaffirms Buy on Cytokinetics, Sees $84 Target Backed by KOL Feedback and FDA Approval Momentum
Truist Securities has reiterated a Buy rating on Cytokinetics with an $84.00 price target — implying roughly 28% upside from the stock's prevailing price of $65.64. The firm points to growing clinical preference for Myqorzo (aficamten) versus Bristol Myers Squibb's Camzyos among new hypertrophic cardiomyopathy patient starts, and it says positive k…